{
    "nctId": "NCT00553410",
    "briefTitle": "Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer",
    "officialTitle": "SOLE, Study of Letrozole Extension, A Phase III Trial Evaluating the Role of Continuous Letrozole Versus Intermittent Letrozole Following 4 to 6 Years of Prior Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone-Receptor Positive, Node Positive Early Stage Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 4884,
    "primaryOutcomeMeasure": "Disease-free Survival (DFS)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the following criteria:\n\n  * Steroid hormone receptor-positive tumors (estrogen receptor and/or progesterone receptor), determined by immunohistochemistry, after primary surgery and before commencement of prior endocrine therapy\n  * Prior local treatment including surgery with or without radiotherapy for primary breast cancer with no known clinical residual loco-regional disease\n  * Following primary surgery, eligible patients must have had evidence of lymph node involvement either in the axillary or internal mammary nodes, but not supraclavicular nodes\n  * Clinically disease-free\n* Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or a sequential combination of both\n\n  * When calculating 4-6 years, neoadjuvant endocrine therapy should not be included\n* No evidence of recurrent disease or distant metastatic disease\n* No prior bilateral breast cancer\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Must be postmenopausal by any of the following criteria:\n\n  * Patients of any age who have had a bilateral oophorectomy (including radiation castration AND amenorrheic for \\> 3 months)\n  * Patients 56 years old or older with any evidence of ovarian function must have biochemical evidence of definite postmenopausal status (defined as estradiol, luteinizing hormone \\[LH\\], and follicle-stimulating hormone \\[FSH\\] in the postmenopausal range)\n  * Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range)\n\n    * Patients who have received prior luteinizing-hormone releasing-hormone (LHRH) analogues within the last year are eligible if they have definite evidence of postmenopausal status as defined above\n* Clinically adequate hepatic function\n* No bone fracture due to osteoporosis at any time during the 4-6 years of prior therapy\n* No prior or current malignancy except adequately treated basal cell or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, or contra- or ipsilateral in situ breast carcinoma\n* No other nonmalignant systemic diseases (cardiovascular, renal, lung, etc.) that would prevent prolonged follow-up\n* No psychiatric, addictive, or any other disorder that compromises compliance with protocol requirements\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 12 months since prior and no other concurrent endocrine SERM/AI therapy\n* Any type of prior adjuvant therapy allowed including, but not limited to, any of the following:\n\n  * Neoadjuvant chemotherapy\n  * Neoadjuvant endocrine therapy\n  * Adjuvant chemotherapy\n  * Trastuzumab (Herceptin\u00ae)\n  * Ovarian ablation\n  * Gonadotropin releasing hormone analogues\n  * Lapatinib ditosylate\n* No concurrent hormone-replacement therapy, bisphosphonates (except for treatment of bone loss), or any other investigational agent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}